Overview

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Status:
Active, not recruiting

Trial end date:
2022-09-30

Target enrollment:

Participant gender:

Summary

Purpose of the study was to assess the effect of enzalutamide on time to Prostate Specific Antigen (PSA) progression as compared to placebo in chemotherapy naïve participants with progressive metastatic prostate cancer who have failed androgen deprivation therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Androgens